Secondary analysis of the pivotal phase 3 trial with DNA sequencing in 184 AML patients: CPX-351 vs 7+3 improved survival only in myelodysplasia-related AML (median 9.7 vs 6.8 months; P=.037), with no benefit in TP53-AML or other-AML.
Secondary analysisn = 184
Shimony et al. CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial